OPA1 and acute myeloid leukemia: In conclusion, our study revealed that inhibition of mitochondrial fusion by MFN2 or OPA1 depletion induce potent anti-leukemic effects ex vivo and in vivo through an inhibition of cell cycle, unveiling a promising new therapeutic approach for AML.